Bivalirudin
![]() |
- ₹10078.08 - ₹40269
- Product name: Bivalirudin
- CAS: 128270-60-0
- MF: C98H138N24O33
- MW: 2180.29
- EINECS:274-570-6
- MDL Number:MFCD08282793
- Synonyms:Bivalirudin, TFA;BIVALIRUDIN;BITTERMELONP.E;Human Bivalirudin;DPHE-PRO-ARG-PRO-GLY-GLY-GLY-GLY-ASN-GLY-ASP-PHE-GLU-GLU-LLE-PRO-GLU-GLU-TYR-LEU;Bivalirudin BG 8967, Hirulog, Hirulog I;BG 8967, Hirulog, Hirulog I;H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
2 prices
Selected condition:
Brand
- Sigma-Aldrich(India)
Package
- 10MG
- 50MG
- ManufacturerSigma-Aldrich(India)
- Product numberSML1051
- Product descriptionBivalirudin trifluoroacetate salt ≥97% (HPLC)
- Packaging10MG
- Price₹10078.08
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberSML1051
- Product descriptionBivalirudin trifluoroacetate salt ≥97% (HPLC)
- Packaging50MG
- Price₹40269
- Updated2022-06-14
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Sigma-Aldrich(India) | SML1051 | Bivalirudin trifluoroacetate salt ≥97% (HPLC) | 10MG | ₹10078.08 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | SML1051 | Bivalirudin trifluoroacetate salt ≥97% (HPLC) | 50MG | ₹40269 | 2022-06-14 | Buy |
Properties
Density :1.52±0.1 g/cm3(Predicted)
storage temp. :-20°C
solubility :≥54.5 mg/mL in DMSO with gentle warming; ≥10.18 mg/mL in EtOH with gentle warming and ultrasonic; ≥43.5 mg/mL in H2O with gentle warming
form :powder
color :white to off-white
Sequence :D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
InChIKey :OIRCOABEOLEUMC-GEJPAHFPSA-N
storage temp. :-20°C
solubility :≥54.5 mg/mL in DMSO with gentle warming; ≥10.18 mg/mL in EtOH with gentle warming and ultrasonic; ≥43.5 mg/mL in H2O with gentle warming
form :powder
color :white to off-white
Sequence :D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
InChIKey :OIRCOABEOLEUMC-GEJPAHFPSA-N
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|
Description
Bivalirudin was launched in New Zealand as an anticoagulant for i.v. treatment of patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. Bivalirubin is a synthetic 20 amino acid peptide rationally modeled on hirudin (residues 53- 64), the most potent and specific naturally-occuring known inhibitor of thrombin, the enzyme that plays a key role in hemostasis and blood clot formation. This peptide is a direct thrombin inhibitor that maintains the unique bivalent binding properties of hirudin to the catalytic site and to the fibrin-recognition exosite of the enzyme, so acting directly on thrombin with high affinity and specificity. In vitro studies demonstrated that alpha- and zeta-thrombins, both with the higher fibrinogen-procoagulant activities, were inhibited. In rats receiving high doses of bivalirudin, the platelet deposition in carotide was reduced by 63% compared to controls. The results of clinical studies, conducted only in patients receiving concomitant aspirin, suggested that the use of bivalirudin was more efficacious and more predictable than unfractionated heparin, with fewer bleeding complications. Despite some unresolved developmental issues, the attractive properties of this novel agent could make it a useful alternative to heparin in a variety of coagulation disorders.Related product price
- Oxytocin
₹4959 - 15-28-Somatostatin-28
₹5109.4-77117.3 - Octreotide acetate
₹28318.2-41232.43